Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talampanel open-label extension in ALS
NCT00982150Phase 2Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Sep 2009
- Primary completion
- Jun 2010
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of talampanel in amyotrophic lateral sclerosis (ALS), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Revised ALS Functional Rating Scale. Started Sep 2009; status: terminated.
02
Drugs
talampanel
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT00982150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00982150.